High efficacy of BPaL among patients infected with Mycobacterium tuberculosis lineage 1 in the Philippines
This study investigated Mycobacterium tuberculosis (MTB) isolates from participants of a Philippine clinical study evaluating the WHO-recommended bedaquiline-pretomanid-linezolid with/without moxifloxacin (BPaL/M) regimen for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB). Whole genome sequencing (WGS) was performed to determine MTB lineage distribution and genomic profiles associated with drug susceptibility. Phenotypic drug susceptibility testing complemented genomic analysis to assess correlations between genotype, drug response, and treatment outcomes. The study aimed to generate genomic evidence from a region where MTB lineage 1 is highly prevalent and to contribute data on BPaL drug susceptibility across different MTB lineages. These data provide insight into the genetic diversity and drug resistance characteristics of MTB isolates circulating in the Philippines and support global understanding of BPaL regimen performance in diverse genetic backgrounds.